Adding Venetoclax to Standard Chemo Doubled Death Rate in Aggressive Lymphoma Trial

A phase II trial testing whether adding the cancer drug venetoclax (Venclexta) to standard chemotherapy could help patients with double-hit lymphoma backfired badly. Patients who got the combination died more often and relapsed faster than those who got standard treatment alone, according to results published in Lancet Haematology.

The trial, run through the Alliance for Clinical Trials in Oncology as study A051701, was stopped early. Investigators pulled the plug after six patients on the venetoclax arm died during treatment, compared with one death in the group that got standard chemotherapy alone.

The Numbers

Double-hit lymphoma is a rare and brutal form of large B-cell lymphoma, making up about 5% of newly diagnosed diffuse large B-cell lymphoma cases, according to the study authors. It carries rearrangements in the MYC gene plus BCL2 and/or BCL6, and standard chemotherapy alone often fails these patients.

The study enrolled 73 patients across 41 hospitals and outpatient clinics in the U.S. between October 2019 and September 2020. Median age was 65, 55% were men, and 89% were white. Patients were randomly assigned to get either DA-EPOCH-R, an intensive chemoimmunotherapy regimen, or that same regimen plus venetoclax, a BCL2 inhibitor.

The results were not close. Median progression-free survival was 28.4 months with DA-EPOCH-R alone versus 7.7 months with venetoclax added, according to lead author Jeremy S. Abramson, MD, of Mass General Brigham Cancer Institute, and his co-authors. At 24 months, 72% of patients on standard treatment were alive compared with 52% of those who got venetoclax, a difference the authors called statistically significant (P=0.038).

Abramson and his co-authors said the added deaths and toxicity came from increased hematologic side effects and infections, with the on-treatment deaths tied primarily to sepsis and cardiac arrest, as Medscape reported. Their conclusion was blunt: "Venetoclax clearly enhances the toxicity of DA-EPOCH-R, and so this combination is not recommended."

Why Anyone Thought This Would Work

The logic behind testing venetoclax wasn't random. Earlier studies had shown the drug held potential benefit for diffuse large B-cell lymphoma patients when paired with R-CHOP, a related chemo regimen, particularly in patients whose tumors overexpressed the BCL2 protein. Double-hit lymphoma patients, by definition, carry BCL2 gene rearrangements, so the combination seemed like a reasonable bet worth testing in a randomized trial.

The Limits of the Data

The trial's early closure cuts both ways. It's the reason regulators and doctors caught the problem before more patients were harmed. It's also the reason the sample size and statistical power are limited, a point the study authors and Medscape both flagged directly.

Other limitations matter too. The trial design let patients receive one cycle of chemotherapy before formal enrollment, which the authors said may have introduced inconsistency into the results. And the study population was 89% white, which the authors acknowledged could limit how well the findings apply to other racial and ethnic groups.

Those caveats are real, and doctors weighing this data for other patient populations should take them seriously. But they don't touch the core signal: six deaths versus one, and a nearly fourfold worse median progression-free survival, are not small effects that vanish under a wider sample size.

The research was funded by grants from the National Cancer Institute at the National Institutes of Health, meaning taxpayer money paid for a trial that stopped a potentially dangerous combination before it reached wider clinical use. Several study authors reported financial ties to pharmaceutical companies including AbbVie, Genentech, and Roche, all disclosed in the published paper.

Andres Gomez, an associate professor of hematology at UANL in Monterrey, Mexico, summarized the finding on social media as a "cautionary tale," writing that more treatment intensity does not automatically mean better outcomes.

What the DA-EPOCH-R arm did show, the authors noted, is a durable benchmark: standard chemoimmunotherapy still produced meaningful remissions in a substantial share of patients. The open question now is what comes next for double-hit lymphoma patients, whose outcomes still lag behind other large B-cell lymphoma cases even under the best current regimen, and whether any of the biomarker-driven approaches still in development can beat 28.4 months without the added lethality venetoclax brought to this trial.